Idiopathic Inflammatory Myopathy clinical trials

Explore recruiting idiopathic inflammatory myopathy clinical trials.

Recruiting idiopathic inflammatory myopathy studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Idiopathic Inflammatory Myopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy

Italy, Spain, Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Nipocalimab in Participants with Active Idiopathic Inflammatory Myopathies

Hungary, Poland, Czechia, Italy, Germany, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

C0251010 - A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)

Bulgaria, Hungary, Sweden, Italy, Poland, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

Slovakia, Spain, Czechia, Italy, Belgium, Netherlands +13 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Idiopathic Inflammatory Myopathy trials by city

Idiopathic Inflammatory Myopathy clinical trials

Recruiting idiopathic inflammatory myopathy studies right now

A Study of AZD0120 in Autoimmune Diseases

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)

A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Safety Study of CC312 in Autoimmune Disease Patients

Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)